Insider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $937,625.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total value of $937,625.00. Following the completion of the sale, the chief executive officer now directly owns 464,058 shares in the company, valued at $66,940,366.50. This trade represents a 1.38 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $140.23 on Thursday. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06. The firm has a market cap of $8.52 billion, a price-to-earnings ratio of 19.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock’s 50-day moving average is $127.64 and its 200-day moving average is $119.71.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Barclays reaffirmed an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Royal Bank of Canada cut their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. TD Cowen cut their price objective on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday. Finally, JPMorgan Chase & Co. boosted their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $182.47.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. CWA Asset Management Group LLC acquired a new position in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after buying an additional 100,112 shares in the last quarter. Centre Asset Management LLC acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth approximately $9,335,000. Moloney Securities Asset Management LLC acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth approximately $464,000. Finally, Pacer Advisors Inc. grew its position in Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after buying an additional 278,465 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.